Healius Ltd (ASX: HLS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Healius Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$980.28 million
P/E Ratio
55.56
Dividend Yield
0.00%
Shares Outstanding
726.13 million
Earnings per share
-0.964
Dividend per share
0.12
Year To Date Return
-17.43%
Earnings Yield
1.80%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Healius Ltd (ASX: HLS)
Latest News
⏸️ Investing
3 growth stocks at reasonable prices
⏸️ Investing
Your instant 3-share cheap portfolio
⏸️ Investing
3 safe dividend stocks that will grow as the population ages
⏸️ Investing
Which are the best healthcare stocks to buy now?
⏸️ Investing
3 healthcare stocks with growing dividends
⏸️ Investing
The stock picker's guide to Primary Health Care Limited in 2014
⏸️ Investing
These 5 healthcare stocks will secure you a healthy financial future
Frequently Asked Questions
-
Yes, Healius has historically paid two fully franked shareholder dividends a year.
-
Healius has generally paid its shareholder dividends in March/April and September/October.
-
Healius Ltd listed on the ASX on 3 July 1998.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 07 Sep 2022 | $0.0600 | 100.00% | Final | 21 Sep 2022 |
| 24 Mar 2022 | $0.1000 | 100.00% | Interim | 05 Apr 2022 |
| 13 Sep 2021 | $0.0675 | 100.00% | Final | 08 Oct 2021 |
| 25 Mar 2021 | $0.0650 | 100.00% | Interim | 15 Apr 2021 |
| 26 Mar 2020 | $0.0260 | 100.00% | Interim | 15 Oct 2020 |
| 29 Aug 2019 | $0.0340 | 100.00% | Final | 27 Sep 2019 |
| 15 Mar 2019 | $0.0380 | 100.00% | Interim | 26 Mar 2019 |
| 27 Aug 2018 | $0.0550 | 100.00% | Final | 17 Sep 2018 |
| 16 Mar 2018 | $0.0510 | 100.00% | Interim | 27 Mar 2018 |
| 31 Aug 2017 | $0.0000 | 100.00% | Final | 18 Sep 2017 |
| 17 Mar 2017 | $0.0480 | 100.00% | Interim | 28 Mar 2017 |
| 01 Sep 2016 | $0.0640 | 100.00% | Final | 19 Sep 2016 |
| 18 Mar 2016 | $0.0560 | 50.00% | Interim | 29 Mar 2016 |
| 26 Aug 2015 | $0.1100 | 50.00% | Final | 14 Sep 2015 |
| 18 Mar 2015 | $0.0900 | 100.00% | Interim | 07 Apr 2015 |
| 27 Aug 2014 | $0.1100 | 100.00% | Final | 15 Sep 2014 |
| 17 Mar 2014 | $0.0900 | 100.00% | Interim | 07 Apr 2014 |
| 16 Sep 2013 | $0.1100 | 100.00% | Final | 08 Oct 2013 |
| 18 Mar 2013 | $0.0650 | 100.00% | Interim | 08 Apr 2013 |
| 17 Sep 2012 | $0.0600 | 100.00% | Final | 08 Oct 2012 |
| 26 Mar 2012 | $0.0500 | 100.00% | Interim | 16 Apr 2012 |
| 19 Sep 2011 | $0.0500 | 100.00% | Final | 10 Oct 2011 |
| 21 Mar 2011 | $0.0300 | 100.00% | Interim | 11 Apr 2011 |
| 20 Sep 2010 | $0.1000 | 100.00% | Final | 11 Oct 2010 |
| 05 Mar 2010 | $0.1500 | 100.00% | Interim | 29 Mar 2010 |
| 07 Sep 2009 | $0.0700 | 100.00% | Final | 28 Sep 2009 |
| 16 Feb 2009 | $0.0700 | 100.00% | Interim | 09 Mar 2009 |
| 08 Sep 2008 | $0.0500 | 100.00% | Final | 09 Oct 2008 |
| 22 Feb 2008 | $0.2200 | 100.00% | Interim | 17 Mar 2008 |
| 31 Aug 2007 | $0.2400 | 100.00% | Final | 24 Sep 2007 |
| 09 Mar 2007 | $0.2100 | 100.00% | Interim | 02 Apr 2007 |
| 09 Oct 2006 | $0.0800 | 100.00% | Special Cash | 30 Oct 2006 |
| 04 Sep 2006 | $0.2200 | 100.00% | Final | 25 Sep 2006 |
| 20 Feb 2006 | $0.2000 | 100.00% | Interim | 13 Mar 2006 |
| 22 Aug 2005 | $0.1300 | 100.00% | Final | 12 Sep 2005 |
| 08 Apr 2004 | $0.0750 | 100.00% | Interim | 03 May 2004 |
HLS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Healius Ltd
Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.
The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres.
The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics.
HLS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Nov 2024 | $1.35 | $0.04 | 3.04% | 1,330,563 | $1.35 | $1.36 | $1.33 |
| 21 Nov 2024 | $1.32 | $-0.03 | -2.24% | 2,846,559 | $1.35 | $1.36 | $1.30 |
| 20 Nov 2024 | $1.34 | $0.03 | 2.29% | 2,074,862 | $1.33 | $1.36 | $1.30 |
| 19 Nov 2024 | $1.31 | $-0.02 | -1.50% | 5,151,328 | $1.33 | $1.38 | $1.30 |
| 18 Nov 2024 | $1.33 | $0.00 | 0.00% | 9,869,052 | $1.28 | $1.33 | $1.22 |
| 15 Nov 2024 | $1.34 | $-0.26 | -16.35% | 12,012,941 | $1.61 | $1.61 | $1.30 |
| 14 Nov 2024 | $1.59 | $0.03 | 1.92% | 2,065,477 | $1.59 | $1.60 | $1.56 |
| 13 Nov 2024 | $1.57 | $-0.02 | -1.27% | 1,201,179 | $1.53 | $1.57 | $1.53 |
| 12 Nov 2024 | $1.58 | $0.00 | 0.00% | 1,320,602 | $1.60 | $1.60 | $1.54 |
| 11 Nov 2024 | $1.58 | $0.00 | 0.00% | 891,611 | $1.58 | $1.60 | $1.58 |
| 08 Nov 2024 | $1.59 | $0.01 | 0.63% | 606,101 | $1.57 | $1.59 | $1.55 |
| 07 Nov 2024 | $1.58 | $0.01 | 0.64% | 3,844,702 | $1.59 | $1.59 | $1.54 |
| 06 Nov 2024 | $1.57 | $0.00 | 0.00% | 1,504,475 | $1.59 | $1.59 | $1.55 |
| 05 Nov 2024 | $1.57 | $-0.01 | -0.63% | 798,106 | $1.56 | $1.57 | $1.55 |
| 04 Nov 2024 | $1.58 | $-0.01 | -0.63% | 663,885 | $1.60 | $1.61 | $1.57 |
| 01 Nov 2024 | $1.59 | $-0.07 | -4.23% | 1,517,155 | $1.65 | $1.65 | $1.58 |
| 31 Oct 2024 | $1.66 | $0.01 | 0.61% | 1,482,813 | $1.64 | $1.66 | $1.63 |
| 30 Oct 2024 | $1.65 | $-0.02 | -1.20% | 724,871 | $1.67 | $1.67 | $1.64 |
| 29 Oct 2024 | $1.67 | $0.00 | 0.00% | 4,534,126 | $1.67 | $1.68 | $1.64 |
| 28 Oct 2024 | $1.67 | $0.00 | 0.00% | 1,402,505 | $1.67 | $1.69 | $1.64 |
| 25 Oct 2024 | $1.67 | $-0.02 | -1.18% | 1,059,389 | $1.69 | $1.72 | $1.67 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Aug 2024 | Sally Evans | Exercise | 16,450 | $25,000 |
Conversion of securities. VWAP
|
| 27 Aug 2024 | Sally Evans | Buy | 16,450 | $25,000 |
Conversion of securities. VWAP
|
| 27 Aug 2024 | Charlie Taylor | Exercise | 16,450 | $25,000 |
Conversion of securities. VWAP
|
| 27 Aug 2024 | Charlie Taylor | Buy | 16,450 | $25,000 |
Conversion of securities. VWAP
|
| 21 May 2024 | Kathryn (Kate) McKenzie | Transfer | 2,559 | $3,224 |
Off-market transfer.
|
| 21 May 2024 | Kathryn (Kate) McKenzie | Transfer | 2,559 | $3,224 |
Off-market transfer.
|
| 14 May 2024 | John Mattick | Transfer | 15,093 | $20,224 |
As advised by the company. Transfer of NED Restricted shares to the custodian under the
Healius NED Share Plan |
| 14 May 2024 | John Mattick | Transfer | 15,093 | $20,224 |
As advised by the company. a transfer of NED Restricted Shares to the custodian
under the Healius NED Share Plan. |
| 14 May 2024 | Gordon Davis | Transfer | 40,214 | $53,886 |
As advised by the company. Transfer of NED Restricted shares to the custodian
under the Healius NED Share Plan. |
| 14 May 2024 | Gordon Davis | Transfer | 40,214 | $53,886 |
As advised by the company. Transfer of NED Restricted shares to the custodian
under the Healius NED Share Plan. |
| 14 May 2024 | Charlie Taylor | Transfer | 16,450 | $22,043 |
As advised by the company. Transfer of NED Restricted shares to the custodian under the
Healius NED Share Plan. |
| 14 May 2024 | Charlie Taylor | Transfer | 16,450 | $22,043 |
As advised by the company. Transfer of NED Restricted shares to the custodian under the
Healius NED Share Plan. |
| 14 May 2024 | Sally Evans | Transfer | 51,332 | $68,784 |
As advised by the company. Transfer of NED Restricted shares to the custodian under the
Healius NED Share Plan. |
| 14 May 2024 | Sally Evans | Transfer | 51,332 | $68,784 |
As advised by the company. Transfer of NED Restricted shares to the custodian under the
Healius NED Share Plan. |
| 15 Mar 2024 | Charlie Taylor | Exercise | 16,450 | $25,000 |
Conversion of securities. vwap, 16,450 NED Share Rights
|
| 15 Mar 2024 | Charlie Taylor | Buy | 16,450 | $25,000 |
Conversion of securities.
|
| 15 Mar 2024 | Sally Evans | Buy | 16,450 | $25,000 |
Conversion of securities. vwap
|
| 15 Mar 2024 | Sally Evans | Exercise | 16,450 | $25,000 |
Conversion of securities. vwap, 16,450 NED Share Rights
|
| 28 Feb 2024 | Maxine Jaquet | Issued | 512,645 | $1,499,999 |
Issue of securities. vwap, 884,504 Performance Rights
|
| 30 Jan 2024 | Maxine Jaquet | Expiry | 1,667,805 | $2,334,927 |
Options expired.
|
| 21 Dec 2023 | Charlie Taylor | Buy | 50,000 | $74,500 |
On-market trade.
|
| 19 Dec 2023 | Charlie Taylor | Buy | 50,000 | $74,815 |
On-market trade.
|
| 14 Dec 2023 | Maxine Jaquet | Issued | 112,078 | $134,493 |
Rights issue.
|
| 14 Dec 2023 | Sally Evans | Issued | 9,557 | $11,468 |
Rights issue.
|
| 14 Dec 2023 | Sally Evans | Issued | 4,110 | $4,932 |
Rights issue.
|
| 14 Dec 2023 | Kathryn (Kate) McKenzie | Issued | 551 | $661 |
Rights issue.
|
| 14 Dec 2023 | Kathryn (Kate) McKenzie | Issued | 9,590 | $11,508 |
Rights issue.
|
| 14 Dec 2023 | John Mattick | Issued | 4,136 | $4,963 |
Rights issue.
|
| 14 Dec 2023 | John Mattick | Issued | 7,546 | $9,055 |
Rights issue.
|
| 14 Dec 2023 | Gordon Davis | Issued | 15,277 | $18,332 |
Rights issue.
|
| 14 Dec 2023 | Gordon Davis | Issued | 11,018 | $13,221 |
Rights issue.
|
| 13 Dec 2023 | Sally Evans | Issued | 32,900 | $50,000 |
Issue of securities. 32,900 NED Share Rights, vwap
|
| 13 Dec 2023 | Charlie Taylor | Issued | 32,900 | $50,000 |
Issue of securities. VWAP, 32,900 NED Share Rights
|
| 04 Dec 2023 | Kathryn (Kate) McKenzie | Buy | 53,000 | $80,560 |
On-market trade.
|
| 01 Dec 2023 | Michael Stanford | Buy | 32,468 | $49,838 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Michael Philip Stanford | Non-Executive Director | Sep 2023 |
Dr Stanford is a member of the People & Governance Committees. Michael has over 20 years of experience as a Chief Executive Officer and Managing Director of multi-campus and multi-service health care organisations with national and international areas of operation, including St John of God Health Care, Australian Hospital Care Ltd, North-Western Health, North-Eastern Health Care Network and Austin & Repatriation Medical Centre.
|
| Professor John Mattick | Non-Executive Director | Mar 2022 |
Professor Mattick is a member of the Risk Management Committees. John is a Professor in the School of Biotechnology and Biomolecular Science at UNSW Sydney. He was Chief Executive of Genomics England and Executive Director of the Garvan Institute of Medical Research. He was a member of the Australian Health Ethics Committee of the National Health & Medical Research Council, an advisor to the Australian Law Reform Commission's Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health.
|
| Mr Gordon Richard Davis | Non-Executive Director | Aug 2015 |
Mr Davis is a member of Risk Management Committees. Prior to becoming a Non-executive Director, Gordon was Managing Director of AWB Limited and served in a senior capacity on various industry associations. He is on the Board of Midway Limited.
|
| Mr Paul Anderson | Chief Executive OfficerManaging Director | Mar 2024 |
Mr Anderson has background in industries facing disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & NZ. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.
|
| Ms Kathryn (Kate) Mary McKenzie | Non-Executive Director | Feb 2021 |
Ms McKenzie is Chair of the Risk Committee and a member of the People & Governance Committee. Kate has corporate governance experience and has held several executive roles, including CEO of Chorus Limited (NZ) and COO of Telstra. She also held the roles of CEO of the NSW Department of Commerce and CEO of WorkCover. She is on the Board of Stockland and Chair of nbnco.
|
| Ms Sally Evans | Non-Executive Director | Aug 2018 |
Ms Evans is Chair of the People & Governance Committee and a member of the Risk Management Committee. Sally has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom, and Hong Kong with responsibilities across the broader Asia Pacific region. She is a board member of Allianz Australia Life, Oceania Healthcare (NZ) and Ingenia Communities.
|
| Mr Charlie Taylor | Non-Executive Director | Mar 2023 |
Mr Taylor has over 30 years of experience in international advisory firms, including as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australia's private and public sector healthcare organisations and initiated multi-year research efforts on healthcare, Covid response, productivity, and innovation. He is also a member of People & Governance Committee.
|
| Mrs Mary Weaver | Company Secretary | Mar 2023 |
-
|
| Mr Stephen Humphries | Company Secretary | Mar 2023 |
-
|
| Steve Humphries | Chief Financial Officer |
-
|
|
| Mary Weaver | Company Secretary |
-
|
|
| Stephen Humphries | Company Secretary |
-
|
|
| Prasad Arav | Group Executive Digital & Technology and Strategy |
-
|
|
| Phil Lucas | Group Executive Lumus Imaging |
-
|
|
| Paula Bayliss | Group Executive People & Culture |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 211,636,287 | 29.15% |
| Citicorp Nominees Pty Limited | 209,962,638 | 28.92% |
| J P Morgan Nominees Australia Pty Limited | 127,569,782 | 17.57% |
| Argo Investments Limited | 22,874,452 | 3.15% |
| BNP Paribas Noms Pty Ltd | 19,666,305 | 2.71% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 12,096,389 | 1.67% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 5,855,473 | 0.81% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 4,335,651 | 0.60% |
| National Nominees Limited | 3,718,898 | 0.51% |
| First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> | 3,469,215 | 0.48% |
| Rinrim Pty Ltd | 2,497,161 | 0.34% |
| HSBC Custody Nominees (Australia) Limited i | 2,037,242 | 0.28% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 939,397 | 0.12% |
| HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 838,693 | 0.12% |
| Netwealth Investments Limited <Wrap Services A/C> | 731,765 | 0.10% |
| Joromada Pty Ltd | 660,000 | 0.09% |
| Buttonwood Nominees Pty Ltd | 658,941 | 0.09% |
| Sep Super Pty Ltd <Sep Super Fund A/C> | 637,236 | 0.09% |
| Mr Gregory Anthony Thomas Bateman | 636,213 | 0.08% |
| Ioof Investment Services Limited <Ips Superfund A/C> | 609,635 | 0.08% |
